Terilyn Monroe Sells 8,571 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 8,571 shares of the business’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total transaction of $977,865.39. Following the completion of the sale, the insider owned 20,990 shares in the company, valued at $2,394,749.10. This represents a 28.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Guardant Health Stock Down 2.2%

Shares of Guardant Health stock opened at $114.75 on Friday. Guardant Health, Inc. has a 12-month low of $34.88 and a 12-month high of $120.74. The stock has a market capitalization of $14.46 billion, a P/E ratio of -35.75 and a beta of 1.58. The company has a 50-day simple moving average of $105.24 and a 200 day simple moving average of $77.45.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. The firm’s revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.88) earnings per share. On average, equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on GH shares. Piper Sandler boosted their price objective on Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Canaccord Genuity Group lifted their price target on Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a report on Monday, December 22nd. TD Cowen reissued a “buy” rating on shares of Guardant Health in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company upped their target price on shares of Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Twenty-one investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $102.81.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health in the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health in the fourth quarter valued at approximately $31,000. IFP Advisors Inc grew its holdings in Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after acquiring an additional 334 shares during the period. Finally, Signaturefd LLC raised its position in shares of Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after acquiring an additional 213 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.